Research has found that Brusatol inhibits the progression of liver cancer by weakening STAT3-driven metastasis in liver cancer cells through altering the levels of epithelial–mesenchymal transition related proteins (Lee et al., 2020). This evidence concerns the gene STAT3 and liver cancer.